Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Mehta-Shah

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
Blood Advances|January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method surveyR Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Blood|February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin LymphomaCatherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
Blood Advances|January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method surveyR Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.
Pageof 9